HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) co-founder and CEO Dr. Jason Mitchell and chief corporate officer Danny Brody were featured on a recent segment of the Cannabis Investing Podcast. The program provides actionable investment insight, context with which to understand the burgeoning cannabis industry, and interviews with C-level executives, scientists, law and sector experts. During their segment, Mitchell and Brody discussed highlights in the cannabis industry, including the recent multibillion deal between GW Pharma and Jazz Pharmaceuticals, as well as radical transparency, the industry’s methodical growth and how companies can become more efficient during COVID-19. They also discussed what makes HempFusion distinctive among other companies operating in the market and prospects of the company going public. From the beginning, HempFusion was committed to compliance, which was a different approach than others operating in the space. That commitment has served the company as the industry has grown and become more regulated; HempFusion is now ahead of the game because it is already compliant. The two also discussed the company’s future strategic plan. Mitchell noted that HempFusion is a completely science-backed company with patented products and proprietary delivery methods, very similar to GW Pharma. “The big fish are now circling,” said HempFusion Wellness co-founder and CEO Dr. Jason Mitchell during the show.
To listen to the podcast, visit https://ibn.fm/zc4N6
About HempFusion Wellness Inc.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in store or online. For more information about the company, visit www.HempFusion.com.
NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.